Should I buy or sell Taysha Gene Therapies stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TSHA shares. View TSHA analyst ratings or view top-rated stocks .

What is Taysha Gene Therapies' stock price target for 2024?

8 Wall Street research analysts have issued 1-year price objectives for Taysha Gene Therapies' shares. Their TSHA share price targets range from $5.00 to $9.00. On average, they predict the company's share price to reach $6.88 in the next year. This suggests a possible upside of 185.3% from the stock's current price. View analysts price targets for TSHA or view top-rated stocks among Wall Street analysts .

How have TSHA shares performed in 2024?

Taysha Gene Therapies' stock was trading at $1.77 on January 1st, 2024. Since then, TSHA stock has increased by 36.2% and is now trading at $2.41. View the best growth stocks for 2024 here .

When is Taysha Gene Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our TSHA earnings forecast .

How were Taysha Gene Therapies' earnings last quarter?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced its quarterly earnings results on Tuesday, March, 19th. The company reported $0.35 EPS for the quarter. The company earned $3.60 million during the quarter, compared to the consensus estimate of $4.75 million.

When did Taysha Gene Therapies IPO?

Taysha Gene Therapies (TSHA) raised $125 million in an initial public offering on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Chardan was co-manager.

Who are Taysha Gene Therapies' major shareholders?

Taysha Gene Therapies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cannon Global Investment Management LLC (0.01%). Insiders that own company stock include John A Stalfort III, Kamran Alam , Paul B Manning , Phillip B Donenberg , RA Session II , Sean P Nolan , Sukumar Nagendran and Suyash Prasad. View institutional ownership trends .

How do I buy shares of Taysha Gene Therapies?

Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TSHA

Taysha Gene Therapies (TSHA) Stock Price, News & Analysis

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Free TSHA Stock Alerts

$2.41

-0.04 (-1.63%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.32
▼
$2.49
50-Day Range: $1.46
▼
$3.25
52-Week Range: $0.50
▼
$3.89

Volume: 1.97 million shs
Average Volume: 2.67 million shs
Market Capitalization: $450.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.88

Get Taysha Gene Therapies alerts:

Taysha Gene Therapies MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 185.3% Upside
$6.88 Price Target
Short Interest: Bearish
9.08% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.48
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.39) to ($0.46) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.19 out of 5 stars

Medical Sector

523rd out of 918 stocks

Biological Products, Except Diagnostic Industry

78th out of 147 stocks

4.5

Analyst's Opinion

Consensus Rating
Taysha Gene Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Taysha Gene Therapies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
9.08% of the outstanding shares of Taysha Gene Therapies have been sold short.
Short Interest Ratio / Days to Cover
Taysha Gene Therapies has a short interest ratio ("days to cover") of 6.1.
Change versus previous month
Short interest in Taysha Gene Therapies has recently increased by 7.46%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Taysha Gene Therapies does not currently pay a dividend.
Dividend Growth
Taysha Gene Therapies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for TSHA.

2.5

News and Social Media Coverage

News Sentiment
Taysha Gene Therapies has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Taysha Gene Therapies this week, compared to 2 articles on an average week.
Search Interest
25 people have searched for TSHA on MarketBeat in the last 30 days. This is an increase of 32% compared to the previous 30 days.
MarketBeat Follows
Only 9 people have added Taysha Gene Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Taysha Gene Therapies insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.25% of the stock of Taysha Gene Therapies is held by insiders.
Percentage Held by Institutions
77.70% of the stock of Taysha Gene Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Taysha Gene Therapies are expected to decrease in the coming year, from ($0.39) to ($0.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Taysha Gene Therapies is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Taysha Gene Therapies is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Taysha Gene Therapies has a P/B Ratio of 6.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Taysha Gene Therapies Stock (NASDAQ:TSHA)

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.

TSHA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TSHA Stock News Headlines

April 15, 2024 | finance.yahoo.com

Certain Biotech Investors Get an Early Look at Results. Is That Fair?

April 14, 2024 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Down 7.5%

April 19, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 13, 2024 | americanbankingnews.com

Needham & Company LLC Reiterates "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA)

April 12, 2024 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Trading 3% Higher

April 11, 2024 | markets.businessinsider.com

Impact and Outlook: Taysha Gene Therapies Stock Analysis

April 11, 2024 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up to $2.68

April 10, 2024 | americanbankingnews.com

Taysha Gene Therapies (NASDAQ:TSHA) Now Covered by Analysts at Piper Sandler

April 19, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 9, 2024 | msn.com

Taysha draws bullish view at Piper Sandler on lead asset

April 9, 2024 | markets.businessinsider.com

Buy Rating on Taysha Gene Therapies with TSHA-102 Poised to Transform Rett Syndrome Treatment and Drive Revenue Growth

April 9, 2024 | markets.businessinsider.com

Evaluating Taysha Gene Therapies: Insights From 7 Financial Analysts

April 5, 2024 | globenewswire.com

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 21, 2024 | seekingalpha.com

Taysha Gene Therapies, Inc. (TSHA) Q4 2023 Earnings Call Transcript

March 21, 2024 | markets.businessinsider.com

Buy Rating on Taysha Gene Therapies Anchored by Promising TSHA-102 Clinical Data and Upcoming Pediatric Study Catalysts

March 21, 2024 | finance.yahoo.com

Taysha Gene Therapies Full Year 2023 Earnings: Beats Expectations

March 21, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Taysha Gene Therapies Amid Positive Clinical Progress and Robust Financial Health

March 20, 2024 | msn.com

Taysha Gene Therapies Shares Jump On Initial Data From First Pediatric Patient With Rare Neurodevelopmental Disorder

March 20, 2024 | markets.businessinsider.com

Buy Rating Reaffirmed for Taysha Gene Therapies Amid Clinical Progress and Financial Stability

March 20, 2024 | msn.com

Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket

March 20, 2024 | msn.com

Taysha Gene Therapies jumps after early data for Rett syndrome candidate

March 20, 2024 | finance.yahoo.com

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2023 Earnings Call Transcript

March 20, 2024 | marketwatch.com

Taysha Gene Therapies Shares Rise 32% After Data on Rett Syndrome Treatment

March 19, 2024 | investorplace.com

TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Beats Revenue for Q4 2023

March 19, 2024 | seekingalpha.com

Taysha Gene Therapies, Inc. 2023 Q4 - Results - Earnings Call Presentation

March 19, 2024 | benzinga.com

Taysha Gene Therapies: Q4 Earnings Insights

March 19, 2024 | benzinga.com

Taysha Gene Therapies Stock Soars On FY23 Results: Here's Why

See More Headlines

Receive TSHA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Taysha Gene Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/19/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:TSHA
CUSIP: N/A
CIK: 1806310
Web: www.tayshagtx.com
Phone: 214-612-0000
Fax: N/A
Employees: 52
Year Founded: 2020

Price Target and Rating

Average Stock Price Target: $6.88
High Stock Price Target: $9.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +185.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.67)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-111,570,000.00
Net Margins: -722.06%
Pretax Margin: -722.06%
Return on Equity: N/A
Return on Assets: -55.72%

Debt

Debt-to-Equity Ratio: 0.54
Current Ratio: 4.08
Quick Ratio: 4.08

Sales & Book Value

Annual Sales: $15.45 million
Price / Sales: 29.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.40 per share
Price / Book: 6.03

Miscellaneous

Outstanding Shares: 187,020,000
Free Float: 182,810,000
Market Cap: $450.72 million
Optionable: Optionable
Beta: 0.29

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Sean P. Nolan (Age 56)
CEO & Chairman
Comp: $674k
Dr. Sukumar Nagendran M.D. (Age 57)
President, Head of Research & Development and Director
Comp: $619.1k
Mr. Kamran Alam CPA (Age 46)
M.B.A., CFO & Corporate Secretary
Comp: $703.61k
Hayleigh Collins
Director & Head of Corporate Communications
Ms. Tracy M. Porter SPHR
Chief People Officer
Mr. Frederick Porter Ph.D.
Chief of Staff & Technical Operations Officer
Ms. Emily McGinnis M.P.H.
Chief Patient Advocacy & External Affairs Officer
Mr. Sean McAuliffe
Chief Business Officer
Dr. Steven Gray Ph.D.
Chief Scientific Advisor of UT Southwestern Gene Therapy Program
Berge Minassian M.D.
Chief Medical Advisor of UT Southwestern Gene Therapy Program

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TSHA Stock Analysis - Frequently Asked Questions

Should I buy or sell Taysha Gene Therapies stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Taysha Gene Therapies in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TSHA shares.
View TSHA analyst ratings or view top-rated stocks.
What is Taysha Gene Therapies' stock price target for 2024?: 8 Wall Street research analysts have issued 1-year price objectives for Taysha Gene Therapies' shares. Their TSHA share price targets range from $5.00 to $9.00. On average, they predict the company's share price to reach $6.88 in the next year. This suggests a possible upside of 185.3% from the stock's current price.
View analysts price targets for TSHA or view top-rated stocks among Wall Street analysts.
How have TSHA shares performed in 2024?: Taysha Gene Therapies' stock was trading at $1.77 on January 1st, 2024. Since then, TSHA stock has increased by 36.2% and is now trading at $2.41.
View the best growth stocks for 2024 here.
When is Taysha Gene Therapies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our TSHA earnings forecast.

How were Taysha Gene Therapies' earnings last quarter?: Taysha Gene Therapies, Inc. (NASDAQ:TSHA) announced its quarterly earnings results on Tuesday, March, 19th. The company reported $0.35 EPS for the quarter. The company earned $3.60 million during the quarter, compared to the consensus estimate of $4.75 million.
When did Taysha Gene Therapies IPO?: Taysha Gene Therapies (TSHA) raised $125 million in an initial public offering on Thursday, September 24th 2020. The company issued 6,600,000 shares at $18.00-$20.00 per share. Goldman Sachs, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Chardan was co-manager.
Who are Taysha Gene Therapies' major shareholders?: Taysha Gene Therapies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cannon Global Investment Management LLC (0.01%). Insiders that own company stock include John A Stalfort III, Kamran Alam, Paul B Manning, Phillip B Donenberg, RA Session II, Sean P Nolan, Sukumar Nagendran and Suyash Prasad.
View institutional ownership trends.
How do I buy shares of Taysha Gene Therapies?: Shares of TSHA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TSHA) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Taysha Gene Therapies (TSHA) Stock Price, News & Analysis

Taysha Gene Therapies MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Taysha Gene Therapies Stock (NASDAQ:TSHA)

TSHA Stock Price History

TSHA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

TSHA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™